NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Roche Holding AG (“Roche” or the “Company”) (OTCQX:RHHBY).
The investigation focuses on whether the Company and its executives violated federal securities laws by misrepresenting the efficacy and cost-effectiveness of its Perjeta-based breast cancer treatment. Specifically, on June 5, 2017, the Company announced reports of an early study comparing the benefits provided to cancer patients when using a combination of Perjeta and the Company’s older cancer drug, Herceptin, versus using Herceptin alone. The study results showed that the combination therapy only provides a marginal benefit compared to Herceptin alone even though the combined therapy has a yearly cost that is double that of the Herceptin treatment. On this news, the Company’s stock dropped as much as 8% during intraday trading on June 5, 2017.
If you invested in Roche stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/RHHBY. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.